User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
  Citation Number 1
 Views 13
 Downloands 1
Bazal bolus insülin tedavisi alan tip 2 diyabetiklerde insülin çeşidi ve günlük dozların tedavi başarısına etkisi
2020
Journal:  
Şişli Etfal Hastanesi Tıp Bülteni
Author:  
Abstract:

GİRİŞ: Çalışmamızın amacı sık aralıklı insülin tedavisi almakta olan tip 2 diyabet hastalarında farklı insülin tiplerini günlük insülin doz ihtiyacı ve tedavi başarısı açısından karşılaştırmak, yüksek dozlara rağmen tedavi başarısızlığının sebeplerini irdelemektir YÖNTEM: Retrospektif olarak dizayn edilmiş olan çalışmamıza bazal bolus insülin tedavisi altındaki 198 tip 2 diyabet hastası dahil edildi. Hastalar aldıkları insülin tiplerine göre 3 gruba ayrıldı (Grup 1: Kısa ve uzun etkili analog insülin alanlar(n: 83), Grup 2: Kısa ve uzun etkili regüler insülin alanlar(n: 58), Grup 3: Regüler insülin + uzun etkili analog insülin alanlar(n: 57)) Hasta takip dosyalarından demografik veriler ve günlük insülin doz bilgileri kaydedildi. Bu veriler ve hedef HbA1c düzeyine ulaşma oranları gruplar arasında karşılaştırıldı. Ayrıca, glisemik hedeflere ulaşılabilen ve ulaşılamayan hastaların insülin dozları karşılaştırıldı. BULGULAR: 198 hastanın 123’ü (%62,1) kadın 65’i (%47,9) erkektir. Üç grubun yaş ortalaması sırasıyla 55,81± 8,1, 58,3 ± 8,9, 58,3± 8,8 dir. HbA1c düzeyleri Grup 1 de 8,72± 1,65, Grup 2 de %9,02± 1,98, Grup 3 de ise %9,05 ± 2,24 saptanmıştır. Hedef A1c değeri %7 nin altına ulaşma oranları analog tedavi grubunda %27,7, regüler tedavi grubunda %25,9, regüler+analog tedavi grubunda ise %31,6 dır (p >0,05). Üç grubun günlük bolus ve bazal insülin dozu, total ve kg başına insülin dozu ve bazal bolus oranı anlamlı farklılık göstermemiştir(p > 0,05). Grup 1 ve Grup 2 de glisemik kontrol hedefine ulaşılamayan hastalarda günlük total insülin dozları,Grup 3 de ise bazal insülin dozu hedefe ulaşılanlardan anlamlı olarak daha yüksek saptandı. SONUÇ: Analog ve regüler insülinler arasında doz analizlerinde belirgin farklılık saptamadığımız çalışmamızda en önemli sonuç olarak yüksek insülin dozlarına çıkmanın glisemik kontrol için yeterli olmayabileceği ortaya konulmuştur. Bu hastalarda altta yatan neden aranmalı, düzeltilebilecek nedenler ortadan kaldırılmalıdır. (SETB-2018-10-140)

Keywords:

Basal bolus insulin treatment in type 2 diabetics the variety of insulin and the effect of daily doses on the treatment success
2020
Author:  
Abstract:

Introduction: The aim of our study is to compare different types of insulin in type 2 diabetic patients who are frequently receiving interim insulin treatment in terms of daily insulin dose needs and therapeutic success, to identify the causes of treatment failure despite high doses Method: Retrospective designed our study included 198 type 2 diabetic patients under basal bolus insulin treatment. Patients were divided into 3 groups according to the types of insulin they received (Group 1: Short and long-effective analog insulin fields(n: 83) , Group 2: Short and long-effective regular insulin fields(n: 58) , Group 3: Regular insulin + long-effective analog insulin fields(n: 57) ) Patient tracking files recorded demographic data and daily insulin dose information. These data and the reach rates to the target level HbA1c were compared between groups. In addition, insulin doses were compared to patients who could and could not reach glycemic targets. 123 of 198 patients (62.1%) are female and 65 (47.9%) are male. The average age of the three groups is 55,81±8,1, 58,3±8,9, 58,3±8,8 respectively. HbA1c levels were 8.72 ± 1.65, 9.02 ± 1.98, and 9.05 ± 2.24 in Group 1. The target value A1c is below 7% in the analog treatment group is 27.7%, in the regular treatment group is 25.9%, and in the regular + analog treatment group is 31.6% (p > 0.05). The daily bolus and basal insulin doses of the three groups, the total and kg insulin doses and the basal bolus ratio did not differ significantly (p > 0,05). In Group 1 and Group 2, the total daily insulin doses were significantly higher in patients who were unable to the target of glycemic control, while in Group 3 the basal insulin doses were significantly higher than in patients who were unable to the target. In our study we did not find a clear difference in dosage analyses between analog and regular insulin, the most important result was that high insulin dosages may not be sufficient for glycemic control. These patients should be searched for the underlying cause, the causes that can be corrected should be eliminated. (SETB 2018-10-140)

Keywords:

Citation Owners
Attention!
To view citations of publications, you must access Sobiad from a Member University Network. You can contact the Library and Documentation Department for our institution to become a member of Sobiad.
Off-Campus Access
If you are affiliated with a Sobiad Subscriber organization, you can use Login Panel for external access. You can easily sign up and log in with your corporate e-mail address.
Similar Articles












Şişli Etfal Hastanesi Tıp Bülteni

Field :   Sağlık Bilimleri

Journal Type :   Ulusal

Metrics
Article : 901
Cite : 1.228
2023 Impact : 0.019
Şişli Etfal Hastanesi Tıp Bülteni